Creso Pharma Ltd's acquisition target Halucenex Life Sciences Inc secures deal with Nucro Technics to test psilocybin liquid formulations
Creso Pharma’s acquisition target Halucenex secures deal with Nucro Technics to test psilocybin liquid formulations It will also provide CPH with the ability to develop and validate methods for potency, component identification and microbiology for botanical psilocybe mushrooms grown in the future at Halucenex. Nucro-Technics employs more than 170 scientific support personnel at its state-of-the-art 60,000 square foot facility in Toronto. Creso Pharma Ltd's (ASX:CPH) (FRA:1X8) target acquisition Halucenex Life Sciences Inc has signed an agreement with leading pharmaceutical co...